Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database.
作者信息
Ma Z, Sun X M, Lu W C, Zhao Z X, Xu Z M, Lyu J Y, Zhao P, Liu L H
机构信息
Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.
出版信息
ESMO Open. 2021 Feb;6(1):100033. doi: 10.1016/j.esmoop.2020.100033. Epub 2021 Jan 11.
Abstract
摘要
相似文献
1
Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database.
ESMO Open. 2021 Feb;6(1):100033. doi: 10.1016/j.esmoop.2020.100033. Epub 2021 Jan 11.
2
Acute myeloid leukemia as an adverse event in a patient treated with a poly(ADP-ribose) polymerase (PARP) inhibitor.
Am J Hematol. 2023 Oct;98(10):1665-1666. doi: 10.1002/ajh.26969. Epub 2023 May 25.
3
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Lancet Haematol. 2021 Feb;8(2):e122-e134. doi: 10.1016/S2352-3026(20)30360-4. Epub 2020 Dec 18.
4
Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.
Eur J Cancer. 2021 Nov;157:59-62. doi: 10.1016/j.ejca.2021.08.016. Epub 2021 Sep 3.
5
Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series.
Blood Cancer J. 2022 Jan 25;12(1):11. doi: 10.1038/s41408-022-00607-7.
6
PARP inhibitors-understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia.
Lancet Haematol. 2021 Feb;8(2):e97-e99. doi: 10.1016/S2352-3026(20)30375-6. Epub 2020 Dec 18.
7
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.
Br J Haematol. 2023 May;201(3):e25-e29. doi: 10.1111/bjh.18766. Epub 2023 Mar 23.
8
Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Oncotarget. 2015 Sep 29;6(29):27490-504. doi: 10.18632/oncotarget.4748.
9
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Haematologica. 2009 May;94(5):638-46. doi: 10.3324/haematol.2008.001933.
10
Poly(ADP-ribose)polymerase inhibitors-associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres.
Br J Haematol. 2022 Feb;196(3):787-793. doi: 10.1111/bjh.17863. Epub 2021 Oct 5.
引用本文的文献
1
Chromatin organization in myelodysplastic syndrome.
Exp Hematol. 2024 Jun;134:104216. doi: 10.1016/j.exphem.2024.104216. Epub 2024 Apr 4.
2
Foxm1 haploinsufficiency drives clonal hematopoiesis and promotes a stress-related transition to hematologic malignancy in mice.
J Clin Invest. 2023 Aug 1;133(15):e163911. doi: 10.1172/JCI163911.
3
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.
Oncologist. 2023 Jul 5;28(7):565-574. doi: 10.1093/oncolo/oyad123.
4
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities.
Int J Mol Sci. 2022 Nov 24;23(23):14672. doi: 10.3390/ijms232314672.
5
Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data.
Front Pharmacol. 2022 Jun 15;13:912256. doi: 10.3389/fphar.2022.912256. eCollection 2022.
6
Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents.
Cancers (Basel). 2022 Feb 14;14(4):953. doi: 10.3390/cancers14040953.
Zotero 插件